Related references
Note: Only part of the references are listed.Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
Michael J. Koren et al.
NATURE MEDICINE (2022)
Statins and Inflammation
Martin Satny et al.
CURRENT ATHEROSCLEROSIS REPORTS (2021)
LPA Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels
Andreja Rehberger Likozar et al.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2021)
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2020)
Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction
Thor Ueland et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers
Renate M. Hoogeveen et al.
JACC-CARDIOVASCULAR IMAGING (2019)
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
Lotte C. A. Stiekema et al.
EUROPEAN HEART JOURNAL (2019)
Low-Grade Inflammation Modifies Cardiovascular Risk Even at Very Low LDL-C Levels: Are We Aiming for a Dual Target Concept?
Wolfgang Koenig
CIRCULATION (2018)
Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
Aruna D. Pradhan et al.
CIRCULATION (2018)
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2018)
Stress and Inflammation in Coronary Artery Disease: A Review Psychoneuroendocrineimmunology-Based
Massimo Fioranelli et al.
FRONTIERS IN IMMUNOLOGY (2018)
Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project
Carmen Garcia-Gomez et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
Claes Held et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subtractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)
Amos Baruch et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States
Steve Varvel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms
Amirhossein Sahebkar et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans
Fleur M. van der Valk et al.
CIRCULATION (2016)
Role of Cytokine Gene Score in Risk Prediction of Premature Coronary Artery Disease
Wafa Omer et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2016)
Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS)
Mehdi Afshar et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans
Nike Mueller et al.
JOURNAL OF LIPID RESEARCH (2015)
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
Iain B. McInnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial
Nihar R. Desai et al.
CIRCULATION (2013)
Association between the Interleukin-6 Promoter Polymorphism-174G/C and Serum Lipoprotein(a) Concentrations in Humans
Heiner K. Berthold et al.
PLOS ONE (2011)
Effects of interventions on oxidative stress and inflammation of cardiovascular diseases
Sewon Lee et al.
WORLD JOURNAL OF CARDIOLOGY (2011)
C-Reactive Protein and Cardiovascular Diseases-Is it Ready for Primetime?
Carl J. Lavie et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2009)
C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the US Preventive Services Task Force
David I. Buckley et al.
ANNALS OF INTERNAL MEDICINE (2009)
Interleukin-6 promoter polymorphism and cardiovascular risk factors: The Health 2000 Survey
Antti Riikola et al.
ATHEROSCLEROSIS (2009)
C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study
Tanja B. Grammer et al.
EUROPEAN HEART JOURNAL (2009)
Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial infarction
Jing Tan et al.
HEART AND VESSELS (2009)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population
Pia R. Kamstrup et al.
CIRCULATION (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
DNA variants, plasma levels and variability of C-reactive protein in myocardial infarction survivors: results from the AIRGENE study
Melanie Kolz et al.
EUROPEAN HEART JOURNAL (2008)
Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels -: a study in twins
M. A. Woerns et al.
GENES AND IMMUNITY (2006)
Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction - Predictive role of C-reactive protein
M Suleiman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
C-reactive protein levels and outcomes after statin therapy
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Genetic effects on baseline values of C-reactive protein and serum amyloid A protein: A comparison of monozygotic and dizygotic twins
AJ MacGregor et al.
CLINICAL CHEMISTRY (2004)
Influence of tumor necrosis factor-308 and C-reactive protein G1059C gene variants on serum concentration of C-reactive protein:: evidence for an age-dependent association
F Araújo et al.
CLINICA CHIMICA ACTA (2004)
Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients
E Ascer et al.
ATHEROSCLEROSIS (2004)
In the elderly, interleukin-6 plasma levels and the-174G>C polymorphism are associated with the development of cardiovascular disease
NS Jenny et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein
MA Vickers et al.
CARDIOVASCULAR RESEARCH (2002)
Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study
JS Pankow et al.
ATHEROSCLEROSIS (2001)
Share Paper
